List view / Grid view
Neoadjuvant cisplatin and pemetrexed in combination with atezolizumab met safety criteria in resectable pleural mesothelioma clinical study.
Mount Sinai researchers reveal that, in a Phase I trial, their personalised cancer vaccines targeting cancer neoantigens showed some early signs of potential benefit.
MIT researchers developed and tested in mice intratracheal vaccines to protect against the vaccinia virus and the formation of lung cancer.
In this article, European Pharmaceutical Review’s Hannah Balfour discusses how COVID-19 has impacted the pharma industry with regard to cancer clinical trial and treatment disruptions.
Imfinzi (durvalumab) has been approved by the European Commission as a first-line treatment for extensive-stage small cell lung cancer, with chemotherapy.
A new drug delivery technology has been developed using nanotubes which can efficiently and precisely target lung cancer cells.
A late-stage clinical trial for Imfinzi and an experimental treatment has not extended the lives of patients with advanced non-small cell lung cancer.
Vizimpro (dacomitinib) has been recommended as a first-line treatment option for patients with lung cancer.
A pharmaceutical company will appeal a decision by NICE to not recommend osimertinib for use within NHS England.
A method using blood tests could enable clinicians to detect and diagnose early-stage lung cancer in order that surgery could be used as a treatment...
Moffitt researchers conducted a Phase III trial which found durvalumab to increase the survival of patients with non-small cell lung cancer...
Improved accuracy and fewer patient side effects are among the benefits claimed for the pioneering radiotherapy machine...
Saliva has been used to measure stress hormones, enzyme levels and cancer mutations...